立体定向放疗用于初治寡转移性肾癌:2b期试验最终结果
主要终点为系统治疗时间(TTST)超过1年的患者比例,结果为91%,中位TTST为55.6个月,中位改良无进展生存期(mPFS)为40个月,局部控制率100%,3年总生存率和癌症特异性生存率分别为68.7%和87.0%。
要点
- 序贯SAbR在未接受系统治疗的寡转移性肾癌中实现91%患者TTST超过1年。
- 中位TTST为55.6个月,中位mPFS为40个月,局部控制率达100%。
- 3年OS为68.7%,CSS为87.0%,健康相关生活质量保持稳定。
核心结论
- 序贯SAbR实现了持久的疾病控制,且未伴随患者报告生活质量的显著变化。
- 结果支持在 selected 寡转移性肾癌患者中采用以生存者为中心、避免早期系统治疗的降阶梯策略。
研究设计与样本
- 前瞻性、单臂、2b期试验。
- 所有转移灶均接受SAbR治疗。
主要发现
- TTST超过1年的患者比例为91%,中位TTST为55.6个月。
- 中位mPFS为40个月,局部控制率为100%。
- 3年OS为68.7%,3年CSS为87.0%。
- 1例患者出现可能归因于SAbR的3级结肠炎,并在免疫治疗后进展为5级。
临床怎么用
- 对于未接受系统治疗的寡转移性肾癌患者,序贯SAbR可作为避免早期系统治疗的一种选择。
局限性
- 单臂设计限制因果推断和普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Management of oligometastatic renal cell carcinoma (omRCC) remains undefined, especially in favorable- and intermediate-risk patients, in whom treatment de-escalation may reduce toxicity and preserve quality of life. This study aims to evaluate sequential stereotactic ablative radiotherapy (SAbR) as first-line therapy in systemic therapy-naïve patients with omRCC. METHODS: A prospective, single-arm, phase 2b trial enrolled systemic therapy-naïve renal cell carcinoma (RCC) patients with three or fewer extracranial metastases, all treated with SAbR to all sites. The primary endpoint was to measure the percentage of patients with time to systemic therapy (TTST) >1 yr. Modified progression-free survival (mPFS) was defined as the earliest time of developing one of the following predefined criteria for local therapy escalation: more than three new metastases, more than six total metastases, local failure at an SAbR-treated site, brain metastases, or lesions not amenable to SAbR. The secondary endpoints included mPFS, progression-free survival on subsequent therapy, overall survival (OS), cancer-specific survival (CSS), local control, toxicity, and health-related quality of life (HRQoL). KEY FINDINGS AND LIMITATIONS: Twenty-three patients received SAbR to 69 lesions. The median follow-up was 45 mo. TTST >1 yr was achieved in 91% of patients; the median TTST was 55.6 mo. The median mPFS was 40 mo. Local control was 100%. The 3-yr OS and CSS rates were 68.7% and 87.0%, respectively. One patient developed grade 3 colitis possibly related to SAbR, progressing to grade 5 following immunotherapy. HRQoL remained stable. Single-arm design limits causal inference and generalizability. CONCLUSIONS AND CLINICAL IMPLICATIONS: Sequential SAbR achieved durable disease control and was not associated with significant changes in patient-reported quality of life, supporting a survivorship-centered, de-escalation strategy that avoids early systemic therapy in selected omRCC patients.
引用
- Hannan R, Assadi R, Christie A, et al. Stereotactic Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer: Final Results of a Phase 2b Trial. Eur Urol Oncol. 2026. PMID: 41486044. doi:10.1016/j.euo.2025.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。